Cargando…

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II

We report on a 6 year old boy with severe MPS II undergoing immune modulation therapy due to high IgG antibody titers to IV idursulfase and no significant decline in urinary GAG levels since initiating enzyme replacement therapy. He has complete deficiency of iduronate-2-sulfatase activity due to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Katherine H., Messinger, Yoav H., Burton, Barbara K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471157/ https://www.ncbi.nlm.nih.gov/pubmed/28649520 http://dx.doi.org/10.1016/j.ymgmr.2014.11.007

Ejemplares similares

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
por: Racoma, Marie Julianne C., et al.
Publicado: (2021)

Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
por: Yee, Karen S., et al.
Publicado: (2023)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy
por: Kim, Katherine H., et al.
Publicado: (2023)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2019)

Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report(,)
por: Kim, Sarah, et al.
Publicado: (2017)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
por: Chan, Mei-Yan, et al.
Publicado: (2023)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Anti-feline panleukopenia virus serum neutralizing antibody titer in domestic cats with the negative or low hemagglutination inhibition antibody titer
por: SOMA, Takehisa, et al.
Publicado: (2018)

Cervical spondylolisthesis in mucopolysaccharidosis type II
por: Rossi, Alessandro, et al.
Publicado: (2022)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
por: Xie, Hongsheng, et al.
Publicado: (2015)

Successful Simultaneous Liver-Kidney Transplantation in the Presence of Multiple High-Titered Class I and II Antidonor HLA Antibodies
por: Paterno, Flavio, et al.
Publicado: (2016)

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
por: Okuyama, Torayuki, et al.
Publicado: (2019)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus
por: Zandman-Goddard, G, et al.
Publicado: (2005)

Successful spinal anesthesia in a patient with mucopolysaccharidosis type I under femoral fracture reduction and external fixation
por: Sun, Lan, et al.
Publicado: (2019)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study
por: Muenzer, Joseph, et al.
Publicado: (2023)

CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
por: Calias, Pericles, et al.
Publicado: (2012)

Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs
por: Uriarte Ecenarro, Miren, et al.
Publicado: (2022)

Baseline Anti-blood Group Antibody Titers and their Response to Desensitization and Kidney Transplantation
por: Shah, B. V., et al.
Publicado: (2017)

Limited Clinical Value of Anti-Retinal Antibody Titers and Numbers in Autoimmune Retinopathy
por: Rujkorakarn, Ploysai, et al.
Publicado: (2023)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Mucopolysaccharidosis Type II: A Kenyan Case Series
por: Mungai, L. N. Wainaina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u7v5hgc3aioe0m72c21udpaekm